Clinical outcomes of patients with advanced NSCLC with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors

被引：0
|
作者：
Gu, Yangchun
Yu, JinYu
Hu, Haifeng
Zhang, Hua
Cao, Baoshan
Liang, Li
机构：
[1] Peking Univ Third Hosp, Beijing, Peoples R China
[2] Yanan City Hosp Tradit Chinese Med, Yanan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21034
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors: A single-center ambispective cohort study
    Gu, Yangchun
    Yu, Jinyu
    Hu, Haifeng
    Zhang, Hua
    Cao, Baoshan
    Liang, Li
    THORACIC CANCER, 2023, 14 (31) : 3147 - 3160
  • [2] Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors
    Rossi, Sabrina
    Toschi, Luca
    Finocchiaro, Giovanna
    Di Noia, Vincenzo
    Bonomi, Maria
    Cerchiaro, Eleonora
    Ceresoli, Giovanni Luca
    Beretta, Giordano Domenico
    D'Argento, Ettore
    Santoro, Armando
    CLINICAL LUNG CANCER, 2019, 20 (02) : 82 - 87
  • [3] EGFR Exon 19 Deletion Is Associated with Favorable Overall Survival After First-Line Icotinib Therapy in Advanced NSCLC Patients
    Zhang, C.
    Hou, H.
    Cheng, X.
    Gong, D.
    Liu, H.
    Yu, H.
    Zhu, W.
    Zhu, J.
    Liu, K.
    Lv, H.
    Zhou, N.
    Cong, J.
    Liu, D.
    Yang, L.
    Jiang, M.
    Zhang, Y.
    Chen, L.
    Zhu, Y.
    Zhang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2139 - S2139
  • [4] Tyrosine kinase inhibitors as first-line treatment in NSCLC
    Maemondo, Makoto
    LANCET ONCOLOGY, 2016, 17 (05): : 541 - 543
  • [5] Predictive impact of different exon 19 deletions in EGFR-mutant NSCLC treated with first-line TKIs
    Rossi, Sabrina
    Toschi, Luca
    Finocchiaro, Giovanna
    D'Argento, Ettore
    Di Noia, Vincenzo Pio
    Cassano, Alessandra
    Bonomi, Maria
    Cerchiaro, Eleonora
    Ceresoli, Giovanni Luca
    Beretta, Giordano D.
    Barone, Carlo
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Association of different EGFR mutations with different outcomes in EGFR-mutated NSCLC patients treated with tyrosine kinase inhibitors.
    Ulivi, Paola
    Petracci, Elisabetta
    Dazzi, Claudio
    Verlicchi, Alberto
    Canale, Matteo
    Chiadini, Elisa
    Capelli, Laura
    Gamboni, Alessandro
    Papi, Maximilian
    Burgio, Marco Angelo
    Mariotti, Marita
    De Luigi, Nicoletta
    Ludovini, Vienna
    Bennati, Chiara
    Chiari, Rita
    Crino, Lucio
    Amadori, Dino
    Delmonte, Angelo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Associations of early adverse events with clinical outcomes in patients with NSCLC treated with EGFR tyrosine kinase inhibitors
    Lin, Fang-Ju
    Lin, Wen-Yen
    Wang, Chi-Chuan
    Shih, Jin-Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] EGFR Tyrosine Kinase Inhibitors and Combination Strategies in First-line Treatment of Advanced NSCLC: A Network Meta-analysis
    de Castro, G.
    Stock, G. T.
    Harada, G.
    Pereira, A. A. L.
    Sadeghirad, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S426 - S427
  • [9] Molecular characteristics of EGFR exon 19 deletion subtypes in NSCLC patients.
    Gu, Weiquan
    Lu, Zhongyu
    Shi, Shulin
    Ma, Juan
    Lu, Guanghua
    Deng, Wanglong
    Ding, Ran
    Bu, Fanfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients
    Su, Jian
    Zhong, Wenzhao
    Zhang, Xuchao
    Huang, Ying
    Yan, Honghong
    Yang, Jinji
    Dong, Zhongyi
    Xie, Zhi
    Zhou, Qing
    Huang, Xiaosui
    Lu, Danxia
    Yan, Wenqing
    Wu, Yi-Long
    ONCOTARGET, 2017, 8 (67) : 111246 - 111257
12345